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Abstract 
The COVID‑19 pandemic has become the leading societal concern. The pandemic has shown that the public health 
concern is not only a medical problem, but also affects society as a whole; so, it has also become the leading scientific 
concern. We discuss in this treatise the importance of bringing the world’s scientists together to find effective solu‑
tions for controlling the pandemic. By applying novel research frameworks, interdisciplinary collaboration promises to 
manage the pandemic’s consequences and prevent recurrences of similar pandemics.
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Background
Coronavirus disease 2019 (COVID-19), the outbreak 
due to severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), has taken on pandemic proportions 
in 2020, affecting more than 1.5 million individuals in 
almost all countries (Date: April 8, 2020) [1]. This alarm-
ing number is still expected to be only the “tip of the 
iceberg”. A global approach is imperative to improve 
healthcare services worldwide to combat COVID-19. 
During this period, many scientists from around the 
world have been conducting projects related to this pan-
demic [2].
Public health is an appropriate and timely discipline for 
conducting interdisciplinary studies. Actions to improve 
public health care require new approaches including the 
involvement of complementary disciplines. Many disci-
plines—such as medicine and pharmacy, molecular and 
cellular biology, microbiology and biochemistry, genetics, 
immunology, pharmacology, nutrition, psychology, epi-
demiology, economics, societal needs, communication 
and political sciences, health and nursing care services, 
physics and chemistry, geography, and statistics or com-
putational sciences for big data management—encom-
pass research perspectives conducive to the observation, 
analysis, understanding, and interpretation of the health 
consequences of COVID-19 [3].
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There are several reasons behind the imperative for 
interdisciplinary research and evidence-based treatment 
of COVID-19. One reason is the request by public health 
policy experts for science-based reports on the feasibil-
ity and efficiency of measures that could be helpful to 
decision-makers, while satisfying community needs and 
aspirations. Collaboration among scientists with an inter-
disciplinary focus can help achieve such a goal [4, 5].
Covid‑19
Coronaviruses (CoVs) are human and vertebrate patho-
gens [6]. They are able to infect humans, poultry, birds, 
insects, rodents,  cats and several wild animal species, 
affecting not only the respiratory system, but also gas-
trointestinal, hepatic, cardiovascular and central nervous 
systems [7, 8].
The present outbreak of COVID-19, initially observed 
in the People’s Republic of China’s Hubei Province, has 
pandemically spread to every country and region of 
the world [9]. The World Health Organization (WHO) 
announced a global health emergency on January 30th, 
2020, based on reports of exponentially increasing cases 
of COVID-19 observed in China and subsequently in 
other locations throughout the world [10]. This global 
health emergency warning came just 1  month after the 
first officially reported case from China [11].
Scientists, infectious disease experts and most govern-
ments around the world took immediate steps to control 
the disease and to carry out epidemiologic, virologic, and 
therapeutic investigations [12].
The importance of interdisciplinary research
The last three decades witnessed a growing trend of col-
laborations among researchers with diverse backgrounds 
of training and education across world regions [13, 14]. 
The literature on the theoretical scope and benefits of 
such collaboration is extensive [15].
Although it is essential through multidisciplinary 
research to establish practical methods for large-scale 
disinfection treatment to inactivate  SARS-CoV-2 in dif-
ferent environmental settings in order to reduce the risk 
of infection, this does not stop the pandemic. Unlike mul-
tidisciplinary research, where researchers from disparate 
fields work either separately or in collaboration, interdis-
ciplinary research refers to teams with varying specialties 
unifying to achieve an overall objective [13, 16, 17].
In this context, Rosenfield [18] took this topic one step 
further by introducing a three-tiered structure for con-
ceptualizing the mechanism of collaboration among dif-
ferent disciplines: (i) in multidisciplinarity, researchers 
work in parallel or sequentially from a disciplinary-spe-
cific base to address a common problem; (ii) in Inter-
disciplinarity, researchers work jointly, but still from a 
disciplinary-specific base to address the common prob-
lem; (iii) finally, in transdisciplinarity, researchers work 
jointly, using a shared conceptual framework drawing 
together disciplinary-specific theories, concepts, and 
approaches to address a common problem [18].
One example of transdisciplinary science relevant to 
the problem of COVID-19 is the integrative science of 
microbiology, molecular pathology (including immunol-
ogy), and epidemiology [19]. This science has synthe-
sized outcomes from analytical methods of microbiology 
(including virology) at laboratory level, together with sta-
tistical analytical frameworks of epidemiology, with data 
on human populations [19].
However, there are difficulties with sufficient contact or 
communication within professions. Lack of confidence, 
lack of expertise, complexities of healthcare, the confus-
ing nature of healthcare environments, and lack of organ-
ization and standardization can become major obstacles 
to successful communication [20, 21].
Now, more than ever, we are in need of widespread 
scientific collaboration [22, 23]. COVID-19 is a medi-
cal problem with immense societal consequences. The 
world’s scientists need to come together to find the 
proper solution for controlling this pandemic event, 
manage its consequences, and prevent future recurrences 
of similar pandemics. We provide examples below on 
how this can be achieved.
Mathematics and computer science
Mathematical and epidemiological simulation plays a 
pivotal role in predicting, anticipating, and controlling 
present and future epidemics. To better understand and 
model the dynamics of a specific infection, researchers 
need to consider the influence of many variables ranging 
from micro-host–pathogen interactions to host-to-host 
encounters, and the prevailing cultural, social, economic, 
and local customs worldwide [24].
In order to have an accurate prediction in a mathemati-
cal model, it is imperative to obtain a precise estimation 
of the involved parameters. Data fitting is the process 
of adjusting models to data and analyzing the accuracy 
of the fit. For reliable parameter estimation, it is critical 
to implement an accurate and transparent protocol for 
counting the number of infected, deceased, and recov-
ered cases and for unifying different protocols at the 
international level [25, 26].
Dynamic simulation, game theory, and spatial mod-
eling play an increasing role in understanding the biology 
of complex systems. These methods can also illustrate 
the dynamics of the relationship between pathogens and 
their host [27].
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Two mathematical models applicable to a pandemic 
like COVID-19 are stochastic and SIR (susceptible-
infected-recovered). Stochastic modeling entails all 
mathematical models with the random variable in the 
function assignment. That is, stochastic modeling uses 
random assignment for forecasting functions, which is 
helpful in the early stages of virus propagation [28]. The 
SIR model has a reasonable predictive power applied to 
situations where individuals infect each other directly 
[29]. However, in recent years spatial structures, and in 
particular network theory (as a model for road networks 
or flight connections) and metapopulation, have proved 
relevant in understanding the complexity of virus propa-
gation [30, 31].
Worldwide, public health agencies use these frame-
works coupled with information technologies such as 
bioinformatics, big data analytics, machine learning, arti-
ficial learning, sensors, and image recognition to assess 
and establish strategies for ever-emerging infectious dis-
eases and to respond to outbreaks [27, 32–34].
Physics, chemistry and engineering sciences
In epidemics of highly infectious diseases, the entire 
community needs to participate in containing the spread 
of the disease. Healthcare workers (HCWs), however, 
have to be especially careful because they are at signifi-
cantly higher risk of infection than the general population 
[35]. Contact precautions by means of personal protec-
tive equipment (PPE) are the major strategy to reduce 
the risk. However, there is uncertainty about which type 
of PPE protects best, what is the optimal way to don and 
remove it, and how to ensure that all HCWs use PPE as 
instructed [36, 37].
Physicists, chemists and engineers play a key role in 
designing and advancing PPE structure and function to 
inhibit COVID-19 spread throughout the communi-
ties [38]. They help in implementing the manufacturing, 
production pipelines, logistics, and commercialization 
of PPE, along with disposable gloves, sanitizing gels, and 
respirators. In such an emergency context, the contribu-
tion of Universities in Engineering and Material Sciences 
can engage in synergy with companies that produce tex-
tiles, anti-wet coatings, ventilators and respirators, and 
can attempt to reconvert their materials and pipelines 
to products useful for combatting the pandemic. For 
example, material science and mechanical engineering 
can help to perform validation tests of newly produced 
PPE, and assist in the preparation of documents for 
approval [39–41]. Furthermore, constructive interaction 
between certification and regulatory entities as well as 
local, regional, and national governments can minimize 
the time to regulatory approval and delivery to the mar-
ket of newly produced PPE. For example, the standard 
catalog UNI decided to give free access to their publica-
tions related to medical device and face mask regulations 
in a move to support interventions against COVID-19. 
The national governments allocate funds to companies to 
help them recover or convert their production to medi-
cal devices. Moreover, private and non-profit organiza-
tions finance small and medium enterprises (SMEs) and 
universities to promote the transfer of research results 
to markets for improving the safety of community health 
workers (CHWs) and, more in general, for tackling the 
immediate social, health and education emergencies.
In addition to PPE production, physics-based tech-
niques play a substantial role in structural biology. The 
majority of biological macromolecular structures are 
obtained by X-ray crystallography. The development of 
physical technologies spurred the first forays into rational 
drug design, in which scientists study the structure and 
function of molecules in order to determine which drugs 
might bind to their targets, and in case of viruses like 
SARS-CoV-2, to prevent them from replicating [42].
Biological sciences
Biological science provide a deeper understanding of 
complex pathogen-host interactions by using remark-
able innovations in molecular biology and computa-
tional biology, developed during the first decade of the 
21st century [43, 44]. We expect that the modern tools 
of molecular biology will provide insight beyond merely 
defining causative agents for newly discovered infec-
tious diseases, but will also address the evolution of  the 
COVID-19 pathogen, the persistence of infectious cycles 
in nature, the analysis of the causes of the pandemic, and 
the susceptibility mechanisms of specific host groups. 
This knowledge will contribute to the creation of DNA 
and RNA banking to study pathogenic factors encoding 
genes [45, 46].
The control of COVID-19 largely depends on two fac-
tors. The first is  to design early diagnostic tools to esti-
mate more accurately the extent of the pandemic and 
provide effective vaccines. Testing kits are an amalgama-
tion of research based on engineering and biomedical 
sciences. They are designed to exhibit high accuracy and 
rapid analysis to minimize the community spread of the 
disease [47]. As for the second factor, in order to arrive 
at a proper vaccine, scientists must identify viral epitopes 
that might be used as therapeutic targets and that not 
only activate the immune systems but also recognize the 
virus as a target [48].
This virus also has arisen various hypotheses among 
scientists who are eager to demonstrate novel disease 
mechanism. According to one hypothesis proposed by 
Jean-Laurent Casanova of Rockefeller University, immu-
nosenescence contributes, at least in part, to the severe 
Page 4 of 7Moradian et al. J Transl Med          (2020) 18:205 
disease and high mortality of the elderly. However, 
equally important is to explain the fatal disease occa-
sionally observed in the young population. For example, 
there may be an underlying inborn error of immunity 
associated with severe COVID-19 that affects younger 
individuals.
Medical sciences
Community health workers (CHWs) are expected to be 
prepared for emerging epidemics, and to promote pan-
demic preparedness by engaging with community-level 
educators and mobilizers, contributing to surveillance 
systems, and filling the gaps in healthcare services [49, 
50].
It appears that nutritional and metabolic status play 
as independent roles in the evolution and clinical com-
plications observed in COVID-19 patients. Scientists are 
looking for food regimens that can enhance the immune 
system. They suggest that bioactive compounds derived 
from functional foods such as Echinacea, Curcumin, or 
quercetin, due to their antioxidant and anti-inflamma-
tory features, can strengthen the immune system. These 
compounds are thought to enhance the vaccine and drug 
effectiveness in affected individuals or even help to pre-
vent infections [51–54]. Some researchers have demon-
strated the antiviral activities of functional compounds 
such as bioactive peptides, lipids, polysaccharides [55–
57]; however, the mechanisms that underlie their action 
are not well understood.
Individuals suffering from diabetes or cardiovascu-
lar diseases have more severe complications and higher 
mortality rate than healthy metabolically controlled 
counterparts, where the inflammatory condition may be 
associated with infection triggering factors [7, 58–61]. 
Genetic predisposition is also expected in some cases 
with severe COVID-19 phenotypes [62].
Medical staff  members strive to improve the health 
of these patients in order to achieve better population 
immunity against infectious diseases epidemics and pan-
demics like COVID-19. This goal can be achieved by 
increasing public access to health care services.
Social and economical sciences
The emergence of disease and the spread of epidem-
ics depend on individuals’ behavior, the social structure 
in which they are embedded, and the political and civic 
environment that make particular social outcomes more 
likely for some than for others [63, 64]. When quarantine 
laws and social encounter restrictions (e.g., social dis-
tancing) are put in effect [65, 66], social scientists must 
be aware of the psychological, mental health, and eco-
nomic aspects of these decisions. Cognitive science, brain 
and mind science, coupled with social and behavioral 
sciences, contribute insights into anxiety and loneliness 
associated with mental disorders under pandemic meas-
ures [67–69].
COVID-19 has immense socio-economic implications. 
With the rapid and comprehensive increase in interna-
tional travel and trade, pandemic incidents will cause 
economic shock waves that go far beyond mainstream 
health sectors and spread beyond the pathogen’s original 
geographic range [70]. For example, analysts forecast that 
the pandemics will result in an estimated annual eco-
nomic decline of 2–3% of global gross domestic product 
(GDP) in the coming year [71]. Economic scientists can 
promote the necessity for businesses to become pan-
demic-resilient by investing in strategic, operational, and 
financial resilience, and have suggested that these steps 
are a duty of care to society and economies.
A key component to the eradication of COVID-19 and 
lessening its impact on global health is inter-govern-
mental cooperation. A coordinated effort is required so 
that all potential factors are taken into consideration to 
reduce the spread of the virus and prevent similar pan-
demics in the future.
Conclusion
During the last few months of the COVID-19 pandemic, 
while political leaders have locked the borders of their 
countries, we witnessed scientists tearing down theirs, 
creating a global collaboration unlike any in history [22]. 
Never before, have so many experts in so many countries 
focused simultaneously on a single topic, COVID-19, and 
with such urgency and resolve. Nearly all other research 
has ground to a halt.
The role and collaboration of International Organiza-
tions related to Health such as WHO, Food and Agri-
culture Organization (FAO), International Union of 
Nutritional Science (IUNS), and Non-Governmental 
Organizations (NGOs) as well as international consortia 
such as Universal Scientific Education and Research Net-
work (USERN) and national and international academies, 
have been recognized as crucial for an integrated knowl-
edge of the novel coronavirus and impacting the effective 
management of COVID-19 around the planet.
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